{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:00:07Z","timestamp":1773090007310,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":2799,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>We have investigated the effects of methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019), i.v., on diastolic blood pressure (DBP) in pithed and pentobarbitone anaesthetized rats.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In pithed rats, the non\u2010selective 5\u2010HT receptor antagonist methiothepin (0.1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) and the \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptor antagonists methoxyidazoxan and yohimbine (1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) showed significant \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoceptor antagonist potency, but methiothepin did not show \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptor antagonist potency. MDMA (1 and 5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) produced pressor responses which were significantly reduced by the \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoceptor antagonist prazosin (0.1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>), yohimbine (1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) or methiothepin (0.1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>), but not by the 5\u2010HT<jats:sub>2<\/jats:sub> receptor antagonist ritanserin (1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In anaesthetized rats, antagonists revealed two phases with three components to the effects of MDMA (5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) on DBP: an initial pressor response, a later pressor component at 1\u2003min, the sustained depressor response. Methoxyidazoxan, methiothepin or the combination ritanserin\/prazosin significantly reduced the initial pressor response, although neither of the latter compounds alone had any effect.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The pressor response to MDMA (5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) at 1\u2003min was converted to a depressor response by prazosin and to a lesser extent methiothepin and methoxyidazoxan.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The depressor response to MDMA (5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) was significantly reduced by methoxyidazoxan (0.1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>), and by the noradrenaline re\u2010uptake blocker cocaine 10\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> but not 1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>. However, the most marked reduction in the depressor response was produced by the combination of methoxyidazoxan and cocaine.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>It is concluded that the initial pressor response to MDMA (5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) in anaesthetized rats involves \u03b1<jats:sub>2<\/jats:sub>\u2010 and possibly \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoceptors and 5\u2010HT<jats:sub>2<\/jats:sub> receptors, the pressor component at 1\u2003min is largely \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoceptor mediated, and the sustained depressor response involves \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptors.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2001) <jats:bold>133<\/jats:bold>, 429\u2013437; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0704094\">10.1038\/sj.bjp.0704094<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0704094","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T21:27:50Z","timestamp":1106947670000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Vascular actions of MDMA involve \u03b1<sub>1<\/sub> and \u03b1<sub>2<\/sub>\u2010adrenoceptors in the anaesthetized rat"],"prefix":"10.1111","volume":"133","author":[{"given":"John","family":"McDaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00506488"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90056-8"},{"key":"e_1_2_7_4_1","first-page":"911","article-title":"3,4\u2010methylenedioxymethamphetamine destroys serotonergic terminals in rat brain: quantification of neurodegeneration by measurement of [3H]\u2010paroxetine\u2010labelled serotonin uptake sites","volume":"242","author":"BATTAGLIA G.","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(86)90207-8"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05124.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659409000444"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701213"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169468"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00569718"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.1987.03390120077027","article-title":"\u2018Eve\u2019 and \u2018ecstasy\u2019. A report of five deaths associated with the use of MDEA and MDMA","volume":"257","author":"DOWLING G.P.","year":"1987","journal-title":"J. Am. Med. Assoc."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1986.10472366"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00167451"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1994.tb03738.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90288-D"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246288"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4328(96)00078-2"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00499107"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1980.tb13069.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/003693309203700508"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1986.10472367"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91354-4"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702875"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15982.x"},{"key":"e_1_2_7_26_1","first-page":"S43","article-title":"Cardiovascular actions of MDMA (\u2018ecstasy\u2019) involve alpha2\u2010adrenoceptors","volume":"48","author":"MCDAID J.","year":"1999","journal-title":"Physiol. Res."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)91222-3"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(98)01228-0"},{"key":"e_1_2_7_29_1","first-page":"521","article-title":"A preliminary, clinical pharmacological assessment of L\u2010659,066, a novel \u03b12\u2010adrenoceptor antagonist","volume":"34","author":"SCHAFERS R.F.","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90303-1"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1395197"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704094","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0704094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:46:19Z","timestamp":1697561179000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0704094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1038\/sj.bjp.0704094"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0704094","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}